Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography

Biological Psychiatry

Volumn 44, Issue 11, 1998, Pages 1090-1098

  Malison, Robert T ^a   Price, Lawrence H ^c   Berman, Robert ^a,b   Van Dyck, Christopher H ^a   Pelton, Gregory H ^a   Carpenter, Linda ^c   Sanacora, Gerard ^a   Owens, Michael J ^d   Nemeroff, Charles B ^d   Rajeevan, Nallakandi ^a,b   Baldwin, Robert M ^a,b   Seibyl, John P ^a   Innis, Robert B ^a,b   Charney, Dennis S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c BUTLER HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

123I CIT; Major depression; Paroxetine; Seratonin transporter platelets; SPECT

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; IODINE 123; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; DEPRESSION; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEROTONIN BRAIN LEVEL; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN STEM; CARRIER PROTEINS; COCAINE; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032401073     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00272-8     Document Type: Article

References (54)

1. Agren H., Mefford I., Rudorfer M., Linnoila M., Potter W. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiat Res. 20:1986;175-193.
2. Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised). 1987;American Psychiatric Association Press, Washington, DC.
3. Asberg M., Ringberger V., Sjoqvist F., Thoren P., Traskman L., Tuck J. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chorimipramine. Clin Pharac Therap. 21:1977;201-207.
4. Backstrom I., Bergstrom M., Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 486:1989;261-268.
5. Baldwin R., Zea-Ponce Y., Zoghbi S., et al. Evaluation of the monoamine uptake site ligand [123I]methyl 3β-(4-iodophenyltropane 2β-carboxylate ([123I] β-CIT) in nonhuman primates pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI . Nucl Med Biol. 20:1993;597-606.
6. Beck A., Ward C., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of Gen Psychiatry. 4:1961;53-63.
7. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse. 12:1992;27-36.
8. Briley M.S., Langer S.Z., Raisman R., Sechter D., Zarifian E. Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science. 209:1980;303-305.
9. Chang L. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci. 25:1978;638-643.
10. 3H]paroxetine . Neuroscience. 27:1988;473-496.
11. D'haenen H., De Waele M., Leysen J. Platelet 3H-paroxetine binding in depressed patients. Psychiatry Res. 26:1988;11-17.
12. De Keyser J., Ebinger G., Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 27:1990;157-161.
13. Ellis P., Salmond C. Is platelet imipramine binding reduced in Depression? A meta-analysis. Biol Psychiatry. 36:1994;292-299.
14. Hamilton M. A rating scale for depression. J Neurology, Neurosurgery Psychiatry. 23:1960;56-62.
15. Hay W. Statistics for the Social Sciences. Second ed. 1973;Holt, Rinehart and Winston, New York.
16. Heils A., Teufel A., Petri S., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 66:1996;2621-2624.
17. Holman B., Carvalho P., Zimmerman R., et al. Brain perfusion SPECT using an annular single crystal camera initial clinical experience . J Nucl Med. 31:1990;1456-1461.
18. Innis R., Malison R., Al-Tikriti M., et al. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse. 10:1992;177-184.
19. Jibson M., Faull K., Csernansky J. Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system. Biol Psychiatry. 28:1990;595-602.
20. 123I]β-CIT pharmacologic characterization of brain uptake in nonhuman primates . Synapse. 13:1993;295-309.
21. Laruelle M., van Dyck C., Bradberry C., et al. Displacement of [123I]IBF equilibrium binding by d-amphetamine to measure in vivo dopamine release. J Nucl Med. 34:1993;48P.
22. 125I]iodophenyl)tropane-2β-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. J Neurochem. 62:1994;978-986.
23. Laruelle M., van Dyck C., Abi-Dargham A., et al. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med. 35:1994;743-754.
24. 3H] paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry. 24:1988;299.
25. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 14:1994;982-994.
26. Lawrence K., Falkowski J., Jacobson R., Horton R. Platelet 5-HT uptake sites in depression three concurrent measures using [3H]imipramine and [3H]paroxetine . Psychopharmacology. 110:1993;235-239.
27. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region [see comments]. Science. 274:1996;1527-1531.
28. 125I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain. J Neurochem. 61:1993;1996-2006.
29. Little K.Y., McLaughlin D.P., Zhang L., et al. Cocaine, Ethanol, and Genotype Effects On Human Midbrain Serotonin Transporter Binding Sites and Mrna Levels. Am J Psychiatry. 155:1998;207-213.
30. Logan J., Dewey D., Wolf A., et al. Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia comparison of simulations and experimental results from PET studies in baboons . Synapse. 9:1991;197-207.
31. Lowry D., Rosebrough N., Farr A., Randall R. Protein measurement with the folin phenol reagent. J Biol Chem. 193:1951;265-275.
32. Maes M., Meltzer H. The serotonin hypothesis of major depression. Bloom F., Kupfer D. Psychopharmacology The Fourth Generation of Progress . 1995;933-943 Raven Press, New York.
33. Mann J., Underwood M., Arango V. Postmortem studies of suicide victims. Watson S.J. Biology of Schizophrenia and Affective Disease. 1996;197-222 American Psychiatric Press, Inc, Washington DC.
34. Marcusson J., Erikson K. [3H]GBR-12935 binding to dopamine uptake sites in the human brain. Brain Res. 457:1988;122-129.
35. 125I]5-Iodo-6-nitro-2-piperazinylquinoline a potent and selective ligand for the serotonin uptake complex . Eur J Pharmacol. 210:1992;103-104.
36. Mazure C., Nelson J., Price L. Reliability and validity of the symptoms of major depressive illness. Archives Gen Psychiatry. 43:1986;451-456.
37. Mellerup E., Plenge P. Why some depressed patients may have low platelet [3H]-imipramine binding. Acta Psychiatr Scand. 82:1990;330-334.
38. Meltzer H., Arora R. Platelet serotonin studies in affective disorders evidence for a serotonergic abnormality? Sandler M., Coppen A., Harnett S. 5-Hydroxytryptamine in Psychiatry A Spectrum of Ideas . 1991;a50-a89 Oxford University Press, New York.
39. Mintun M., Raichle M., Kolbourn M., Wooten G., Welch M. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 15:1984;217-227.
40. Nemeroff C.B., Knight D.L., Franks J., Craighead W.E., Krishnan K.R.R. Further studies on platelet serotonin transporter binding in depression. Amer J Psychiatry. 151:1994;1623-1625.
41. Nemeroff C.B., Knight D.L., Krishnan K.R.R., et al. Marked reduction in the number of platelet [3H]-imipramine binding sites in geriatric depression. Archives Gen Psychiatry. 45:1988;919-923.
42. Ogilvie A.D., Battersby S., Bubb V.J., et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression [see comments]. Lancet. 347:1996;731-733.
43. Owens M., Nemeroff C. Role of serotonin in the pathophysiology of depression focus on the serotonin transporter . Clinical Chemistry. 40:1994;288-295.
44. Owens M, Nemeroff C (1997): The serotonin transporter and depression. Depression and Anxiety (in press).
45. Owens M.J., Ballenger C.A., Knight D.L., Nemeroff C.B. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. J Pharmacol Exp Ther. 278:1996;1040-1049.
46. Pirker W., Asenbaum S., Kasper S., et al. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 100:1995;247-256.
47. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse. 11:1992;134-139.
48. Spitzer R., Williams J., Gibbon M., First M. Structured Clinical Interview for DSMj-III-R-Patient Edition (SCID-P, Version 1.0). 1990;American Psychiatric Press, Washington, DC.
49. 125I]RTI-55 in vitro binding and autoradiographic characterization . J Neurochem. 62:1994;549-556.
50. Suehiro M., Scheffel U., Dannals R., Hayden T., Ricaurte G., Wagner H. A PET radiotracer for studying serotonin uptake sites carbon-11-McN-5652Z . J Nucl Med. 34:1993;120-127.
51. USP XXIII (1995): Sterility tests (71), The United States Pharmacopeia, 23rd Revision ed. Rockville, MD: United States Pharmacopeial Convention, Inc., pp 1686-1690.
52. Volkow N., Wang G.-J., Fowler J., et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse. 16:1994;255-262.
53. Wall S., Innis R., Rudnick G. Binding of the cocaine analog 2β-carbomethoxy-3β-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters different ionic requirements for substrate and 2β-carbomethoxy-3β-(4-[125I]iodophenyl)tropane binding . Mol Pharmacol. 43:1993;264-270.
54. Young L., Wong D., Goldman S., et al. Effects of endogenous dopamine on kinetics of [3H]methylspiperone and [3H]raclopride binding in the rat brain. Synapse. 9:1991;188-194.